Feature | November 01, 2013

SORT-OUT VI Shows Noninferiority Between Newer DES with Biodegradable and Biocompatible Polymers

Results of the SORT-OUT VI trial presented at TCT 2013

November 1, 2013 — A study found that both drug-eluting stents (DES) with biocompatible polymers and DES with biodegradable polymers were associated with low major adverse coronary events, demonstrating the non-inferiority of the biocompatible polymer stents in patients undergoing percutaneous coronary intervention (PCI). The findings of the SORT-OUT VI trial were presented at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013).
 
To date, there are no large-scale randomized comparison studies of biodegradable polymer-coated stents and biocompatible polymer-coated stents in all-comer populations. The SORT-OUT VI trial investigated the safety and efficacy of a durable but biocompatible polymer coated Resolute Integrity zotarolimus-eluting stent compared with a biodegradable polymer-coated Nobori biolimus A9-eluting stent. 
 
SORT-OUT VI was a multicenter, all-comer, non-inferiority trial that randomized 2,999 patients with stable coronary artery disease or acute coronary syndromes. The trial was performed within the framework of the Scandinavian Organization for Randomized Trials with Clinical Outcomes and used patient-driven clinical event detection through Danish health care registries. 
 
Patients were randomized to receive either a zotarolimus-eluting permanent polymer stent (n = 1,502) or a biolimus-eluting biodegradable stent (n = 1,497). The primary endpoint was a composite of major adverse cardiac events including cardiac death, myocardial infarction and target lesion revascularization after 12 months. 
 
After 12 months, the percentage of patients with major adverse cardiac events was similarly low in both the zotarolimus-eluting and biolimus-eluting stent groups (5.3 percent and 5.1 percent respectively), demonstrating the non-inferiority of the zotarolimus-eluting stent. 
 
“The SORT-OUT VI trial found that both zotarolimus-eluting and the biolimus-eluting stents were associated with low major adverse cardiac events,” said Bent Raungaard M.D., chief physician and associate professor, Aalborg University Hospital, Denmark and lead investigator of the study. “Further, the zotarolimus-eluting stent was found to be non-inferior to the biolimus-eluting stent for patients treated with PCI.”
 
Raungaard reports no relevant conflicts of interest. The SORT-OUT VI trial was supported by unrestricted grants from Biosensors and Medtronic CardioVascular.
 
For more information: www.crf.org

Related Content

Hospital Readmissions Analysis Across All Ages, Insurance Types Identifies High-Risk Groups
News | Business| July 20, 2017
July 20, 2017 — Clinician-researchers at Beth Israel Deaconess Medical Center (BIDMC) recently published a first-of-i
3-D Vascular Ultrasound Quantifies Plaque Burden to Estimate Cardiovascular Risk
News | Cardiovascular Ultrasound| July 20, 2017
July 20, 2017 — In a large, first-of-its-kind population, researchers found an experimental technique known as...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG| July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Sponsored Content | Videos | CT Angiography (CTA)| July 18, 2017
Matthew Budoff, M.D., FACC, professor of medicine, David Geffen School of Medicine at UCLA, endowed chair of preventi
Low Doses of Radiation Could Harm Cardiovascular Health
News | Radiation Dose Management| July 17, 2017
Ionizing radiation, such as X-rays, has a harmful effect on the cardiovascular system even at doses equivalent to...
First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Arterial Disease (PAD)| July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Edwards Sapien 3 TAVR valve will be implanted in asymptomatic aortic stenosis patients in the EARLY TAVR Trial
Feature | Heart Valve Technology| July 14, 2017
July 14, 2017 — Morristown Medical Center, part of Atlantic Health System, has randomized the first patient in the wo
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
SanBio Receives $20 Million Grant for Stroke Clinical Trial
News | Stroke| July 12, 2017
July 12, 2017 — SanBio Inc.
Overlay Init